Home > Reports > Epigenetics Market Size, Share and Forecast to 2030 | Straits Research

Epigenetics Market

Epigenetics Market: Information by Product (Instruments, Reagents & Kits), Application (Oncology, Autoimmune Diseases), and Region — Forecast till 2030

Published At : 21 Jul, 2022
Updated At : 15 Nov, 2022
Table of Content Download Sample

Market Snapshot

Base Year:
2021
Study Period:
2020-2030
CAGR:
17.05 %
Fastest Growing Market:
Asia-Pacific
Largest Market:
North America

The global Epigenetics Market size was valued USD 2.86 billion in 2021 and is predicted to reach USD 11.83 billion by 2030, increasing at a CAGR of 17.05% from 2022 to 2030. Epigenetics studies how cells influence gene function without altering DNA sequence. "Epi" means above in Greek, thus "epigenetic" refers elements beyond the genetic code. Epigenetic alterations alter DNA to turn on or off genes. These DNA alterations don't modify the sequencing of DNA building units. The epigenome is all of the alterations to a cell's DNA that affect gene activity (expression). Epigenetic alterations affect cell protein production by turning on or off genes. This control ensures that cells only create required proteins. Bone-growth proteins aren't made by muscle cells. Patterns of epigenetic change vary among persons, tissues, and cells within a tissue. The epigenome can be affected by food and pollution. Epigenetic changes can be passed from cell to cell and inherited across generations. The epigenetics industry is predicted to develop as sequencing costs fall, the use of next-generation sequencing expands globally, and the products themselves improve. Epigenetics instruments are expensive, and there is a shortage of experts in epigenetics research. These issues are stifling market expansion. Many chronic diseases and disorders, including cardiovascular disease, autoimmune disease and neurodegenerative disorder, are being related to epigenetic mechanisms, such as DNA methylation, histone modification and non-coding RNA, which have a substantial impact on epigenetic processes.

Epigenetics Market Share

Get more information on this report Download Sample Report

Market Dynamics

Global Epigenetics Market Drivers

  • Increasing prevalence of cancer

Cases of cancer are increasing all over the world. As per the World Health Organization, in the year 2020 there were more than 2.1 million newly diagnosed cases of cancer all across the world. Low- and middle-income countries have been responsible for around 70 percent of all fatalities caused by cancer. In the United States, one out of every four people who die has cancer. DNA methylation that is not under proper control has been linked to the development and progression of cancer. The study of epigenetics has revealed novel approaches to the treatment of cancer's dysregulation. There are currently a number of cancer research studies that make use of epigenetics, and these efforts are receiving significant funding. Drugs that have been developed through exhaustive research on epigenetics have proven to be highly effective against a particular form of cancer. As a result, the overall cost of treatment can be decreased, and developing and underdeveloped nations can receive treatment at prices that are more affordable. Epigenetics enables concentrated therapeutic activities that target just damaged and malignant cells within the host, in contrast to the standard cancer treatments. Therefore, an increase in the total number of cancer cases around the world is anticipated to be a significant driver of growth in the epigenetics business.

  • Innovations In Technology, As Well As Increased Efforts in Research & Development

DNA methylation and the alteration of histones are two of the most important technologies utilized in epigenetics. Histones can be modified in a variety of ways by a wide variety of enzymes, including histone deacetylases (HDACs) and histone methyltransferases. It has been found that inhibitors of these enzymes are effective biomarkers for the research and development of epigenetic medicines. The therapeutic sector of the epigenetic research is receiving an increased amount of attention. A significant number of pharmaceutical and biotechnology businesses, in addition to university research groups, are working together to foster the expansion of this industry. This is one of the high-impact key drivers that is propelling the epigenetics market currently.

Global Epigenetics Market Restraints

  • The High Prices Act as A Barrier to Widespread Adoption of Epigenetics

The equipment used for epigenetic study can be quite pricey. They are sophisticated in terms of the technological features they offer, but they require expensive maintenance and additional costs, both of which have the potential to impede the expansion of the epigenetics market. The fact that many research institutions do not have large finances to purchase these instruments is one of the obstacles that prevents their more widespread use. The overall cost of ownership is increased even more by the recurring costs of maintenance and a number of other indirect expenses, such as the cost of samples and consumables. Numerous such systems are necessary for the operation of pharmaceutical corporations and research facilities. As a result, substantial financial investments are necessary in order to acquire a number of expensive genetic instruments. Therefore, the high cost of the instruments is a barrier to their widespread acceptance, which is projected to restrain the growth of the market over the forecast period.

Global Epigenetics Market Opportunities

  • Increasing DNA Methylation Potential

Due to the DNA methylation procedure, which is the covalent attachment of a methyl group to the cytosine ring and inhibits transcription, the epigenetics market has significant potential. A PCR that is sensitive to methylation is known as a methylation-sensitive PCR (MSP). It is possible to use methylation detection methods such as real-time PCR, methylation fluorescence, and quantitative allele methylation analysis as MSP variants. Allele-specific bisulphite sequencing, the southern approach, bisulphite pyrosequencing, and bisulphite PCR followed by MALDI-TOF MS are currently accessible quantitative approaches for DNA methylation. In the future, technological advances will make it easier to evaluate genome-wide the methylation of specific loci in DNA, which opens up new opportunities for the global Epigenetics Market.

Segment Overview

The Global Epigenetics Market is divided into different segments according to the product, application, end user, and geographies.

By Product, Enzymes, kits, tools, and reagents are the categories that fall under this category. The enzymes segment is further subdivided into reverse transcriptase, RNA ligases, and other RNA-modifying enzymes; DNA ligases; DNA polymerases; and acetylases; methyltransferases; and other protein-modifying enzymes. The kits section of the epigenetics market share is further classified into the following categories: RNA sequencing kits, whole genome amplification kits, 5-hmC & 5-mC analysis kits, and Chip sequencing kits. The instrument sector can be further subdivided into the following categories: mass spectrometers; next-generation sequencers; qPCRs; syndicators; and others. The reagents section is further broken down into sub-sections for things like antibodies, buffers, histones, magnetic beads, primers, and others.

By Application, the global market for epigenetics is split into two different categories: oncology and non-oncology. The oncology sector can be further subdivided into the solid tumors segment and the liquid tumors section. In addition to treating cancer, non-oncology applications treat metabolic illnesses, infectious diseases, inflammatory diseases, cardiovascular diseases, and other conditions.

By End-Users, the global market for epigenetics may be broken down into four different types of end users: academic and government research institutes, pharmaceutical and biotechnology businesses, and contract research organizations (CROs). The two most important types of End-User companies are Pharmaceutical and Biopharmaceutical Companies, as well as Biotechnology Companies.

By Geography, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions that make up the various submarkets of the global epigenetics market. Because of significant investments made by pharmaceutical and biotech companies, improved healthcare infrastructure, rising per capita income, early availability of therapies approved for use, and the presence of state-of-the-art research labs and institutions in the region, North America held a dominant share of the global market.

Regional Overview

The Global Epigenetics Market is segmented by geography into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Regional Growth Insights Request Sample Pages

North America is the dominating region among all the remaining regions. Rapid advancements in healthcare infrastructure, the presence of key businesses in the region, significant investments in research and development, and the increased prevalence of malignancies, among other factors, have all contributed to the expansion. Because many mammalian proteins, such as growth hormone, insulin, antibodies, and vaccines, are manufactured industrially, an increase in demand for protein expression systems is projected. In the United States, there is a growing demand for cancer therapy development, and significant investments are being made in cancer genomics research, which is projected to fuel the market's expansion in North America. According to the US National Institute of Health, cancer genomics funding was USD 1,098 million in 2020 and is predicted to reach USD 1,152 million in 2022, according to the US National Institute of Health in December 2021. Greater funding for cancer genomics in the United States is likely to lead to increased usage of epigenetics in research, propelling the market forward throughout the forecast period.

Furthermore, the increased cancer prevalence in the region is fuelling market growth. According to the American Cancer Society (ACS), in the United States, an estimated 1,918,030 new cases and 609,360 deaths are projected in 2022, and cancer is the top cause of death for people over 65. As a result of the increased use of epigenetics in cancer research, the market will continue to develop.

Furthermore, increased investments in epigenetics research by market participants in the United States are likely to propel the market in this area forward. For example, Chroma Medicine, Inc. (Chroma), a new genomic medicine business that pioneered epigenetic editing, started in November 2021 with USD 125 million in funding to address a wide range of disorders and become the technology of choice for gene regulation. As a result of the factors listed above, the market in this region is predicted to grow.

Asia-Pacific will experience the highest growth rate over the course of the forecast period. This is attributable to the rise in awareness regarding epigenetics market growth, the boost in penetration of main players in emerging countries in Asia-Pacific, and the advancement in infrastructure for research and clinical settings. In addition, according to the projections for the epigenetics market in the Asia-Pacific region, both China and India would experience rapid expansion at a high compound annual growth rate.

Major key Players

  1. Illumina, Inc. (US)
  2. Merck KGaA (Germany)
  3. Element Biosciences, Inc.
  4. QIAGEN (Germany)
  5. Hoffmann-La Roche Ltd (Switzerland)
  6. Eisai Co., Ltd. (Japan)
  7. Novartis AG (Switzerland)
  8. Abcam plc (UK)
  9. Zymo Research Corporation. (US)
  10. Cellcentric (Germany)
  11. Domainex (UK)
  12. Agilent Technologies, Inc. (US)
  13. EpiGentek Group Inc. (US)
  14. BioVision Inc. (US)
  15. Bio-Techne. (US)

Recent Developments

  • February 2022 - Element Biosciences, Inc., creator of a revolutionary DNA sequencing technology, has partnered with Dovetail Genomics to demonstrate the value and performance of Dovetail's proximity ligation-based NGS library prep solutions on Element's AVITI System.
  • December 2021 - Qiagen partnered with Denovo Biopharma to provide a revolutionary biomarker solution in 2021. Through this partnership, the firms planned to create a blood-based companion diagnostic test to identify patients with Denovo Genomic Marker 1 likely to accept Denovo's investigational cancer medication DB102TM for treatment of diffuse large B-cell lymphoma, a common lymphoid malignancy.
  • December 2021 - Agilent Technologies partnered with Lonza in Dec-2021. This alliance aims to change how tailored cell treatments are made.
  • October 2021 - Abcam acquired BioVision in Oct. 2021. BioVision would boost Abcam's innovation and computational scale for biochemical and cellular assays. Abcam would gain BioVision's products, abilities, and 70-person development and production teams.

Market Segmentation

By Product

  • Instruments
  • Reagents & Kits
  • Others

By Application

  • Oncology
  • Autoimmune Diseases
  • Metabolic Diseases
  • CNS/Pain Diseases
  • Cardiovascular Diseases
  • Others

By End-User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutions
  • Contract Research Organizations (CROs)
  • Other End-Users

By Geography

  • North America
  • Europe
  • Asia Pacific (APAC)
  • Latin America
  • Middle East and Africa (MEA)
Free Sample Report

"Find new revenue generation opportunities"